Skip to main content
S&P 5007,659.83-1.25%DOW52,795.36-0.11%NASDAQ26,059.57-2.41%BTC$81,313.00-3.91%ETH$2,381.99-5.33%GOLD$4,060.40-2.16%OIL$99.35+2.26%
Smart Investors Daily
SID Premium
DA

NASDAQ · DARE

Daré Bioscience, Inc.

Healthcare · Biotechnology

$0.69

Down-$0.05 (-6.56%)

Updated Oct 22, 2026, 5:44 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
19.81M
P/E ratio
-1.52
Dividend yield
0.00%
52-week range
$0.67 – $3.78
Volume
24.81K
Avg. volume
140.35K

Price performance · DARE

DARE price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 21, 2026

DARE closed at $0.69 after 21 trading sessions, down 14.79% for the selected period.

Last close
$0.69
Period change
-14.79%
Period low
$0.69
Period high
$0.85
Daily close
View OHLC price history
DARE OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 21, 2026$0.68$0.7118$0.6734$0.68824.81K
Oct 20, 2026$0.7231$0.7297$0.67$0.689217.69K
Oct 19, 2026$0.7273$0.7381$0.68$0.706251.99K
Oct 16, 2026$0.7392$0.7397$0.7126$0.724677.21K
Oct 15, 2026$0.73$0.7462$0.7204$0.7496.95K
Oct 14, 2026$0.7426$0.7426$0.7203$0.72961.04K
Oct 13, 2026$0.786$0.786$0.73$0.7477116.07K
Oct 12, 2026$0.77$0.7901$0.7381$0.750181.98K
Oct 9, 2026$0.79$0.7904$0.7601$0.773470.04K
Oct 8, 2026$0.7862$0.80$0.755$0.7722170.79K
Oct 7, 2026$0.8143$0.8194$0.79$0.79113.41K
Oct 6, 2026$0.83$0.88$0.83$0.833188.57K
Oct 5, 2026$0.833$0.8689$0.8308$0.8431157.17K
Oct 2, 2026$0.869$0.8775$0.8224$0.8428148.4K
Oct 1, 2026$0.86$0.8701$0.83$0.851135.13K
Sep 30, 2026$0.80$0.88$0.7683$0.8533278.07K
Sep 29, 2026$0.7869$0.8671$0.7356$0.815644.39K
Sep 28, 2026$0.79$0.816$0.7012$0.75698.47K
Sep 25, 2026$0.77$0.7895$0.7458$0.7755119.24K
Sep 24, 2026$0.8023$0.8456$0.7117$0.7405469.51K
Sep 23, 2026$0.85$0.8699$0.80$0.8074100.04K

Latest DARE news

The latest Smart Investors Daily articles mentioning DARE.

Stock researchCompany · Overview

DARE research

Overview

Company profile and research snapshot.

Company profile

Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$12.00
Implied upside
—
Analysts
—
DARE recent ratings
DateFirmRatingTarget
Dec 2, 2025HC Wainwright & Co.Buy—
Sep 4, 2025Maxim GroupBuy—
Apr 1, 2025HC Wainwright & Co.Buy—
Dec 17, 2024HC Wainwright & Co.Buy—
Nov 15, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 13, 2026

Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and Opportunities

New video series featuring Founder, President and CEO Sabrina Martucci Johnson will provide investors with insights into Daré Bioscience’s growing commercial portfolio, clinical pipeline and strategic priorities Access the CEO Corner here SAN DIEGO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the launch of its

Yahoo · Oct 8, 2026

Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting

Medical Director Annie Thurman, MD, FACOG to present adverse event and relative bioavailability data comparing topical Sildenafil Cream with oral sildenafil in healthy male adultsSAN DIEGO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that clinical data from a Phase 1 study that evaluated the Company’s proprieta

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By